2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
10
Neoplasms
7
Anxiety Disorders
6
Head and Neck Neoplasms
3
Depression
3
Ovarian Neoplasms
2
Hot Flashes
2
Chronic Pain
2
Xerostomia
1
Vomiting
1
Uterine Cervical Neoplasms
1
Testicular Germ Cell Tumor
1
Tendinopathy
1
Smoking Cessation
1
Sleep Wake Disorders
1
Sarcoma
1
Radiculopathy
1
Pulmonary Disease, Chronic Obstructive
1
Prostatic Neoplasms
1
Pathophobia
1
Pain, Postoperative
1
Pain
1
Nociceptive Pain
1
Neuralgia, Postherpetic
1
Neuralgia
1
Nausea
1
Myocarditis
1
Musculoskeletal Pain
1
Melanoma
1
Medication Adherence
1
Interventions
pembrolizumab
300
Nivolumab
273
Ipilimumab
250
aldesleukin
137
Cyclophosphamide
136
Interleukin-2
105
trametinib
82
dabrafenib
76
Temozolomide
75
Dacarbazine
74
Vemurafenib
71
fludarabine
68
fludarabine phosphate
62
Biopsy
49
binimetinib
47
sargramostim
44
Radiosurgery
44
Bevacizumab
43
Paclitaxel
42
encorafenib
40
incomplete Freund's adjuvant
39
atezolizumab
38
Radiotherapy
37
Specimen Handling
36
Cisplatin
36
CTLA-4 Antigen
36
Magnetic Resonance Spectroscopy
35
Carboplatin
35
cobimetinib
34
Introns
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Hypnosis
×
Clear all
NCT04899492
2024-11-07
RESPIRE
Institut Cancerologie de l'Ouest
Phase NA
Terminated
22 enrolled